Interviewtimes 
The whole country is in turmoil in the second wave of the coronavirus epidemic. Although the infection has largely declined, the case load has not decreased. The Defense Research and Development Organization (DRDO)’s Covid vaccine Two-Deoxy-D-Glucose, has emerged as the saviour in India. The Union Minister of Defense unveiled the drug on May 19, while the Director General of Controlling Drugs of India (DCGI) approved the use of the drug. The drug is now available at government hospitals and the Department of Defense’s Covid Care Centers.
Guidelines were issued on Tuesday in which cases and how patients will be able to use the medication, as developed by DRDO with the Radiation Laboratory. According to the guidelines, DRDO recommends the use of the drug in Covid patients. Commercial production of the drug began in the country on Tuesday. Which will soon be available in all hospitals and medical stores.
DRDO recommends that the drug be administered to patients under the direct supervision of a doctor. The medication can be given to critically ill patients from the first to the first 10 days of infection. The drug, which is available in sachet, is said to be effective in reducing the risk of infection by mixing with water.
However, the drug is not recommended for use by people under the age of 18 and breastfeeding mothers. It is also important to note that this drug has not been tested in patients with uncontrolled diabetes, serious heart problems, serious respiratory problems (ARDS), and critically ill and kidney patients. However, the DRDO has indicated that the doctor should use the drug as soon as possible in 10 days of infection.
